Choline alfoscerate

Drug Profile

Choline alfoscerate

Alternative Names: Brezal; Choline alphoscerate; Choline glycerophosphate; Delecit; Gliatilin

Latest Information Update: 05 Nov 2009

Price : $50

At a glance

  • Originator Italfarmaco
  • Developer Dong Wha Pharmaceutical; Italfarmaco
  • Class Antibacterials; Antidementias; Glycerophosphates; Glycerophospholipids; Neuroprotectants; Nootropics
  • Mechanism of Action Cell membrane permeability enhancers; Cholinergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Cognition disorders

Most Recent Events

  • 20 Mar 2003 A study has been added to the adverse events and therapeutic trials sections
  • 22 May 1998 Launched for Cognition disorders in South Korea (IM)
  • 16 Apr 1996 Launched for Cognition disorders in Italy (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top